Mass General Brigham researchers report that the cholesterol-lowering drug evolocumab can significantly reduce the risk of a first major cardiovascular event in people with diabetes who are considered high risk but do not yet have diagnosed…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply